Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.

ABSTRACT:

Background

Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of hepatitis C virus (HCV) treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource.

Objective

To determine the tolerability and feasibility of using direct-acting antivirals (DAAs) as prophylaxis before and after kidney transplantation from HCV-infected donors to non-HCV-infected recipients (that is, HCV D+/R- transplantation).

Design

Open-label nonrandomized trial. (ClinicalTrials.gov: NCT02781649).

Setting

Single center.

Participants

10 HCV D+/R- kidney transplant candidates older than 50 years with no available living donors.

Intervention

Transplantation of kidneys from decea

SUBMITTER: Durand CM 

PROVIDER: S-EPMC6108432 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature